Sort   by:  
 Page size 
MetabolomicsDissection of two routes to naïve pluripotency using different kinase inhibitors
Embryonic stem cells (ESCs) can be maintained in the naïve state through inhibition of Mek1/2 and Gsk3 (2i). A relevant effect of 2i is the inhibition of Cdk8/19, which are negative regulators of the Mediator complex, responsible for the activity of enhancers. Inhibition of Cdk8/19 (Cdk8/19i) stimul...
2021-02-10 | MTBLS301 | MetaboLights
MetabolomicsAnalysis of the effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Muscle Metabolism In Vivo
Not available
ORGANISM(S): Mus musculus 
ST000896 | MetabolomicsWorkbench
MetabolomicsAnalysis of the effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Metabolism In Vivo
Not available
ORGANISM(S): Mus musculus 
ST000893 | MetabolomicsWorkbench
MetabolomicsAnalysis of the effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Liver Metabolism In Vivo
Not available
ORGANISM(S): Mus musculus 
ST000894 | MetabolomicsWorkbench
MetabolomicsAnalysis of the effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Serum Metabolism In Vivo using Non-Targeted Metabolomics Analysis
Not available
ORGANISM(S): Mus musculus 
ST000895 | MetabolomicsWorkbench
TranscriptomicsCharacterising the cellular activity of new Fibroblast Growth Factor Receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
Fibroblast growth factor receptors (FGFRs) can act as driving oncoproteins in certain cancers due to mutation, over-expression or activating gene fusions and are therefore attractive drug targets. Here we have characterized tumour cell responses to three new inhibitors of FGFR1-3, AZ12576089, AZ129...
ORGANISM(S): Homo sapiens 
2012-10-02 | E-TABM-1222 | biostudies-arrayexpress
ProteomicsProteomic profiling by array of tyrosine kinase activity in metastatic malignant melanoma from human tissue specimens
Tyrosine kinase activity profiling of metatstatic malignant melanoma and normal skin tissue samples was performed using peptide kinase arrays. All samples were run in triplicates with and withouth inhbitor PLX4032 and Sutent Malate in order to identify how tyrosine kinases responds to kinase inhibit...
ORGANISM(S): Homo sapiens 
2013-01-17 | E-MTAB-1245 | biostudies-arrayexpress
ProteomicsEvaluation of phospho-tyrosine antibodies for label-free phosphoproteomics
In the past decade multiple tyrosine kinase inhibitors (TKIs) have been implemented in standard treatment regimens for patients with cancer. Unfortunately the majority of patients develops resistance to these drugs. Reliable tools for analysis of pharmacodynamic effects and drug resistance mechanism...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2016-10-21 | MSV000080270 | MassIVE
ProteomicsProbing tyrosine kinase inhibitors specificity
Using a three-pronged MS-based proteomic approach, we assessed the mode-of-action of four clinically-relevant tyrosine kinase inhibitors in an epithelial cancer cell line. Here we defined the: (I) semi-quantitative tyrosine kinome; (II) drug interactome; and (III) drug-induced effects on the tyrosin...
ORGANISM(S): Homo sapiens (Human) 
2014-05-12 | PXD000681 | Pride
Human Tyrosine kinase inhibitors Chemical proteomics Phosphoproteomics Phosphotyrosine Lc-ms/ms 
ProteomicsBead-based kinase phosphorylation profiling identifies SRC as a therapeutic target in glioblastoma
Here we describe a bead-based method capable of profiling tyrosine kinase phosphorylations in a multiplexed, high-throughput and low-cost manner. This approach allows for the discovery of tyrosine kinase-activating events, even when the DNA sequence is wild-type. In an effort to pilot the establishm...
ORGANISM(S): Homo sapiens 
2010-06-24 | E-GEOD-13808 | biostudies-arrayexpress
Sort   by:  
 Page size